High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
1.19B
+0.14%
0.199
-33.7%
1.09B
+5.35%
0.132
+1.91%
1.08B
+5.94%
0.144
+3.02%
Estimates Revision
The market is revising Upward the revenue expectations for Elanco Animal Health Incorporated (ELAN) for FY2025, with the revenue forecasts being adjusted by 0.87% over the past three months. During the same period, the stock price has changed by 74.88%.
Revenue Estimates for FY2025
Revise Upward
+0.87%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.46%
In Past 3 Month
Stock Price
Go Up
+74.88%
In Past 3 Month
8 Analyst Rating
0Wall Street analysts forecast ELAN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAN is 13.58 USD with a low forecast of 10.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
3 Hold
0 Sell
Moderate Buy
0Current: 14.760
Low
10.00
Averages
13.58
High
17.00
0Current: 14.760
Low
10.00
Averages
13.58
High
17.00
Stifel
Jonathan Block
Buy
maintain
$16 -> $17
2025-07-02
Reason
Stifel
Jonathan Block
Price Target
$16 -> $17
2025-07-02
maintain
Buy
Reason
Stifel analyst Jonathan Block raised the firm's price target on Elanco to $17 from $16 and keeps a Buy rating on the shares. Stifel likes Elanco's setup into 2Q25 results, and the stock remains the firm's favorite idea within Animal Health, the analyst tells investors in a research note. Stifel expects operating margin to expand for the first time in four years in 2026.
William Blair
William Blair
Market Perform -> Outperform
upgrade
2025-06-26
Reason
William Blair
William Blair
Price Target
2025-06-26
upgrade
Market Perform -> Outperform
Reason
William Blair upgraded Elanco to Outperform from Market Perform.
William Blair
William Blair
Market Perform -> Outperform
upgrade
2025-06-26
Reason
William Blair
William Blair
Price Target
2025-06-26
upgrade
Market Perform -> Outperform
Reason
TD Cowen
Steve Scala
Buy
maintain
$12 -> $15
2025-05-21
Reason
TD Cowen
Steve Scala
Price Target
$12 -> $15
2025-05-21
maintain
Buy
Reason
TD Cowen analyst Steve Scala raised the firm's price target on Elanco to $15 from $12 and keeps a Buy rating on the shares.
Stifel
Buy
maintain
$15 -> $16
2025-05-19
Reason
Stifel
Price Target
$15 -> $16
2025-05-19
maintain
Buy
Reason
Stifel
Buy
maintain
$13 -> $15
2025-05-08
Reason
Stifel
Price Target
$13 -> $15
2025-05-08
maintain
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Elanco Animal Health Inc (ELAN.N) is 17.98, compared to its 5-year average forward P/E of 20.58. For a more detailed relative valuation and DCF analysis to assess Elanco Animal Health Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
20.58
Current PE
17.98
Overvalued PE
28.61
Undervalued PE
12.55
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
14.44
Current EV/EBITDA
12.69
Overvalued EV/EBITDA
17.91
Undervalued EV/EBITDA
10.98
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
2.03
Current PS
1.57
Overvalued PS
2.85
Undervalued PS
1.22
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areSelling! The selling amount has increased1243.75%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ELAN News & Events
Events Timeline
(ET)
2025-07-09
08:31:01
Elanco receives USDA approval for TruCan Ultra CIV H3N2/H3N8
2025-06-12 (ET)
2025-06-12
16:19:29
Elanco's Zenrelia granted positive opinion by EU veterinary product committee
2025-05-28 (ET)
2025-05-28
07:30:38
Elanco backs FY25 adjusted EPS view 80c-86c, consensus 84c
Sign Up For More Events
Sign Up For More Events
News
Preview
4.0
07-17BenzingaThis Mondelez International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Preview
4.0
07-17CNBCHere are Thursday's biggest analyst calls: Apple, Nvidia, Tesla, McDonald's, Netflix, CoreWeave, First Solar & more
Preview
4.0
07-17BenzingaLeerink Partners Upgrades Elanco Animal Health to Outperform, Announces $18 Price Target
Sign Up For More News
People Also Watch
FAQ
What is Elanco Animal Health Inc (ELAN) stock price today?
What is Elanco Animal Health Inc (ELAN)'s business?
What is the price predicton of ELAN Stock?
What is Elanco Animal Health Inc (ELAN)'s revenue for the last quarter?
What is Elanco Animal Health Inc (ELAN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Elanco Animal Health Inc (ELAN)'s fundamentals?
How many employees does Elanco Animal Health Inc (ELAN). have?